Novartis Caught In Aredia, Zometa Ad Fib

Law360, New York (May 28, 2010, 3:08 PM ET) -- Finding that Novartis Pharmaceutical Corp. failed to come clean about consumer ads for its controversial Aredia and Zometa drugs, a federal judge has granted plaintiffs in the multidistrict litigation additional discovery, potentially aiding allegations that Novartis downplayed the dangers associated with the bone cancer drugs.

On Thursday, Magistrate Judge Joe Brown of the Middle District of Tennessee granted the plaintiffs’ steering committee further discovery to determine the extent Novartis advertised Aredia and Zometa to its consumers, a practice the defendant had expressly denied, but the court...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers